Patents by Inventor Matthew E. Voss
Matthew E. Voss has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9682978Abstract: The present invention provides 2,6,7 substituted purines as described herein or a pharmaceutically acceptable salt thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.Type: GrantFiled: February 4, 2014Date of Patent: June 20, 2017Assignee: Merck Sharp & Dohme Corp.Inventors: Matthew P. Christopher, Francesc Xavier Fradera Llinas, Michelle Machacek, Michelle Martinez, Michael Hale Reutershan, Manami Shizuka, Binyuan Sun, Christopher Francis Thompson, B. Wesley Trotter, Matthew E. Voss, Liping Yang
-
Patent number: 9637493Abstract: The present invention provides substituted pyrrolopyrimidines of Formula I as described herein or a pharmaceutically acceptable salt or solvate thereof: The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.Type: GrantFiled: December 18, 2013Date of Patent: May 2, 2017Assignee: Merck Sharp & Dohme Corp.Inventors: Christopher Dinsmore, Francesc Xavier Fradera Llinas, Amit Ashokro Kudale, Michelle Machacek, Michael Hale Reutershan, Christopher Francis Thompson, B. Wesley Trotter, Liping Yang, Michael D. Altman, Stephane L. Bogen, Ronald J. Doll, Matthew E. Voss
-
Patent number: 9540377Abstract: The present invention provides 2,6,7,8 Substituted Purines as described herein or a pharmaceutically acceptable salt thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.Type: GrantFiled: January 29, 2014Date of Patent: January 10, 2017Assignee: Merck Sharp & Dohme Corp.Inventors: Carolyn Michele Cammarano, Matthew P. Christopher, Christopher Dinsmore, Ronald J. Doll, Francesc Xavier Fradera Llinas, Chaomin Li, Michelle Machacek, Michelle Martinez, Latha G. Nair, Weidong Pan, Michael Hale Reutershan, Manami Shizuka, Dietrich P. Steinhuebel, Binyuan Sun, Christopher Francis Thompson, B. Wesley Trotter, Yaolin Wang, Liping Yang, Stephane L. Bogen, Matthew E. Voss, Jagannath Panda, Anthappan Tony Kurissery
-
Publication number: 20150368247Abstract: The present invention provides 2,6,7 substituted purines as described herein or a pharmaceutically acceptable salt thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.Type: ApplicationFiled: February 4, 2014Publication date: December 24, 2015Applicant: MERCK SHARP & DOHME CORP.Inventors: Matthew P. Christopher, Francesc Xavier Fradera Llinas, Michelle Machacek, Michelle Martinez, Michael Hale Reutershan, Manami Shizuka, Binyuan Sun, Christopher Francis Thompson, B. Wesley Trotter, Matthew E. Voss, Liping Yang
-
Publication number: 20150353553Abstract: The present invention provides 2,6,7,8 Substituted Purines as described herein or a pharmaceutically acceptable salt thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.Type: ApplicationFiled: January 29, 2014Publication date: December 10, 2015Applicant: MERCK SHARP & DOHME CORP.Inventors: Carolyn Michele Cammarano, Matthew P. Christopher, Christopher Dinsmore, Ronald J. Doll, Francesc Xavier Fradera Llinas, Chaomin Li, Michelle Machacek, Michelle Martinez, Latha G. Nair, Weidong Pan, Michael Hale Reutershan, Manami Shizuka, Dietrich P. Steinhuebel, Binyuan Sun, Christopher Francis Thompson, B. Wesley Trotter, Yaolin Wang, Liping Yang, Stephane L. Bogen, Matthew E. Voss, Jagannath Panda, Anthappan Tony Kurissery
-
Publication number: 20150329548Abstract: The present invention provides substituted pyrrolopyrimidines as described herein or a pharmaceutically acceptable salt or solvate thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.Type: ApplicationFiled: December 18, 2013Publication date: November 19, 2015Applicant: Merck Sharp & Dohme Corp.Inventors: Christopher Dinsmore, Francesc Xavier Fradera Llinas, Amit Ashokro Kudale, Michelle Machacek, Michael Hale Reutershan, Christopher Francis Thompason, B. Wesley Trotter, Liping Yang, Michael D. Altman, Stephane L. Bogen, Ronald J. Doll, Matthew E. Voss
-
Patent number: 9062071Abstract: The present invention provides a compound of Formula I (The formula should be inserted here) as described herein or a pharmaceutically acceptable salt or solvate thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.Type: GrantFiled: December 17, 2012Date of Patent: June 23, 2015Assignee: Merck Sharp & Dohme Corp.Inventors: Yao Ma, Manami Shizuka, Timothy J. Guzi, Yuan Liu, Yuan Tian, Brian R. Lahue, Craig R. Gibeau, Gerald W. Shipps, Jr., Yaolin Wang, Stephane L. Bogen, Latha G. Nair, Weidong Pan, Mark A. McCoy, Matthew E. Voss, Margarita Kirova-Snover, W. Bent Clayton
-
Patent number: 8962611Abstract: The present invention provides substituted imidazopyridines as described herein or a pharmaceutically acceptable salt or solvate thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.Type: GrantFiled: August 21, 2014Date of Patent: February 24, 2015Assignee: Merck Sharp & Dohme Corp.Inventors: Matthew P. Christopher, Francesc Xavier Fradera Llinas, Michelle Machacek, Michelle Martinez, Michael Hale Reutershan, Manami Shizuka, Binyuan Sun, Christopher Francis Thompson, B. Wesley Trotter, Matthew E. Voss, Michael D. Altman, Stephane L. Bogen, Ronald J. Doll
-
Publication number: 20140357618Abstract: The present invention provides substituted imidazopyridines as described herein or a pharmaceutically acceptable salt or solvate thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.Type: ApplicationFiled: August 21, 2014Publication date: December 4, 2014Inventors: Matthew P. Christopher, Francesc Xavier Fradera Llinas, Michelle Machacek, Michelle Martinez, Michael Hale Reutershan, Manami Shizuka, Binyuan Sun, Christopher Francis Thompson, B. Wesley Trotter, Matthew E. Voss, Michael D. Altman, Stephane L. Bogen, Ronald J. Doll
-
Patent number: 8895543Abstract: The present invention relates to derivatives of vinca alkaloids. Pharmaceutical compositions containing these compounds as well as processes of preparation and treatment of various conditions are also disclosed.Type: GrantFiled: April 6, 2007Date of Patent: November 25, 2014Assignee: Albany Molecular Research, Inc.Inventors: Ian L. Scott, Jeffrey M. Ralph, Matthew E. Voss
-
Publication number: 20140336222Abstract: The present invention provides a compound of Formula 1 as described herein or a pharmaceutically acceptable salt, solvate or ester thereof. The compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and methods of treating cancer using the same.Type: ApplicationFiled: July 24, 2014Publication date: November 13, 2014Inventors: Stephane L. Bogen, Yao Ma, Yaolin Wang, Brian Robert Lahue, Latha G. Nair, Manami Shizuka, Matthew E. Voss, Margarita Kirova-Snover, Weidong Pan, Yuan Tian, Bheemashankar A. Kulkarni, Craig R. Gibeau, Yuan Liu, Giovanna Scapin, Diane Rindgen, Ronald J. Doll, Timothy J. Guzi, Danny J. Hicklin, Amin Nomeir, Cynthia Seidel-Dugan, Gerald W. Shipps, JR., Malcolm MacCoss
-
Publication number: 20140323482Abstract: The present invention provides a compound of Formula I (The formula should be inserted here) as described herein or a pharmaceutically acceptable salt or solvate thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.Type: ApplicationFiled: December 17, 2012Publication date: October 30, 2014Inventors: Yao Ma, Manami Shizuka, Timothy J. Guzi, Yuan Liu, Yuan Tian, Brian R. Lahue, Craig R. Gibeau, Gerald W. Shipps, JR., Yaolin Wang, Stephane L. Bogen, Latha G. Nair, Weidong Pan, Mark A. McCoy, Matthew E. Voss, Margarita Kirova-Snover, W. Bent Clayton
-
Patent number: 8846657Abstract: The present invention provides substituted imidazopyridines as described herein or a pharmaceutically acceptable salt or solvate thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.Type: GrantFiled: December 18, 2013Date of Patent: September 30, 2014Assignee: Merck Sharp & Dohme Corp.Inventors: Matthew P. Christopher, Francesc Xavier Fradera Llinas, Michelle Machacek, Michelle Martinez, Michael Hale Reutershan, Manami Shizuka, Binyuan Sun, Christopher Francis Thompson, B. Wesley Trotter, Matthew E. Voss, Michael D. Altman, Stephane L. Bogen, Ronald J. Doll
-
Publication number: 20140179680Abstract: The present invention provides substituted imidazopyridines as described herein or a pharmaceutically acceptable salt or solvate thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.Type: ApplicationFiled: December 18, 2013Publication date: June 26, 2014Inventors: Matthew P. Christopher, Francesc Xavier Fradera Llinas, Michelle Machacek, Michelle Martinez, Michael Hale Reutershan, Manami Shizuka, Binyuan Sun, Christopher Francis Thompson, B. Wesley Trotter, Matthew E. Voss, Michael D. Altman, Stephane L. Bogen, Ronald J. Doll
-
Patent number: 8222421Abstract: Certain chemical entities chosen from compounds of Formula 1 and pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, and prodrugs thereof, are provided herein. Pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicles chosen from carriers, adjuvants, and excipients, are also provided herein. Methods of treating patients suffering from certain diseases and disorders responsive to angiogenic kinase modulation, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include cancer, including breast neoplasia, endometrial cancer, colon cancer, and neck squamous cell carcinoma. Methods of treatment include administering at least one chemical entity as a single active agent or administering such at least one chemical entity in combination with one or more other therapeutic agents.Type: GrantFiled: July 20, 2010Date of Patent: July 17, 2012Assignee: Gilead Connecticut, Inc.Inventors: Scott A. Mitchell, Mihaela Diana Danca, Peter A. Blomgren, David R. Brittelli, Pavel Zhichkin, Matthew E. Voss
-
Patent number: 8053428Abstract: The present invention relates to novel vinorelbine derivatives. Pharmaceutical compositions containing these compounds as well as processes of preparation and processes of use for treatment of various conditions are also disclosed.Type: GrantFiled: April 6, 2007Date of Patent: November 8, 2011Assignee: Albany Molecular Research, Inc.Inventors: Ian L. Scott, Jeffrey M. Ralph, Matthew E. Voss
-
Patent number: 7842802Abstract: The present invention relates to novel vinorelbine derivatives. Pharmaceutical compositions containing these compounds as well as processes of preparation and processes of use for treatment of various conditions are also disclosed.Type: GrantFiled: December 10, 2008Date of Patent: November 30, 2010Assignee: Albany Molecular Research, Inc.Inventors: Ian L. Scott, Jeffrey M. Ralph, Matthew E. Voss
-
Publication number: 20100286190Abstract: Certain chemical entities chosen from compounds of Formula 1 and pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, and prodrugs thereof, are provided herein. Pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicles chosen from carriers, adjuvants, and excipients, are also provided herein. Methods of treating patients suffering from certain diseases and disorders responsive to angiogenic kinase modulation, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include cancer, including breast neoplasia, endometrial cancer, colon cancer, and neck squamous cell carcinoma. Methods of treatment include administering at least one chemical entity as a single active agent or administering such at least one chemical entity in combination with one or more other therapeutic agents.Type: ApplicationFiled: July 20, 2010Publication date: November 11, 2010Inventors: Scott A. Mitchell, Mihaela Diana Danca, Peter A. Blomgren, David R. Brittelli, Pavel Zhichkin, Matthew E. Voss
-
Patent number: 7777040Abstract: Certain chemical entities chosen from compounds of Formula 1 and pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, and prodrugs thereof, are provided herein. Pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicles chosen from carriers, adjuvants, and excipients, are also provided herein. Methods of treating patients suffering from certain diseases and disorders responsive to angiogenic kinase modulation, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include cancer, including breast neoplasia, endometrial cancer, colon cancer, and neck squamous cell carcinoma. Methods of treatment include administering at least one chemical entity as a single active agent or administering such at least one chemical entity in combination with one or more other therapeutic agents.Type: GrantFiled: May 2, 2006Date of Patent: August 17, 2010Assignee: CGI Pharmaceuticals, Inc.Inventors: Scott A. Mitchell, Mihaela Diana Danca, Peter A. Blomgren, David R. Brittelli, Pavel Zhichkin, Matthew E. Voss
-
Patent number: 7745619Abstract: The present invention relates to derivatives of vinca alkaloids. Pharmaceutical compositions containing these compounds as well as processes of preparation and treatment of various conditions are also disclosed.Type: GrantFiled: October 31, 2007Date of Patent: June 29, 2010Assignee: Albany Molecular Research, Inc.Inventors: Ian L. Scott, Jeffrey M. Ralph, Matthew E. Voss